Inhibition of the 3CL Protease and SARS-CoV‑2 Replication by Dalcetrapib
E. Niesor, G. Boivin, E. Rhéaume, et al.
ACS Omega
June 2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
D. Rhainds, C. Packard, M. Brodeur, et al.
AHA Journals
April 2021
The GenE Trial: A case study of precision medicine in the cardiovascular setting
Donald M Black MD, Therese Heinonen DVM, Marc Pfeffer MD and Jean-Claude Tardif MD
The Journal of Precision Medicine
August 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Schwartz G., Leiter L., Ballantyne C., et al.
American Diabetes Association: Diabetes Care
May 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
Tardif J.C., Dubé M. P., Pfeffer M, et al.
American Heart Journal
April 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Schwartz G., Leiter L., Ballantyne C, et al.
Diabetes Care
March 2020
Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
Black, D.M., Bentley, D., Chapel, S., et al.
Clinical Pharmacokinetics
November 2018
Adenylate Cyclase Type 9 (ADCY9) Inactivation Protects from Atherosclerosis Only in the Absence of Cholesteryl Ester Transfer Protein (CETP)
Rautureau Y., Deschambault V., Higgins M. E., et. al.
Circulation
April 2018
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes
Tardif J.C., Rhainds D., Brodeur M., et al.
Circulation: Cardiovascular Genetics
August 2016
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib.Circulation Cardiovascular Genetics
Tardif J.C., Rheaume E., Lemieux Perreault L-P., et. al.
Circulation: Cardiovascular Genetics
January 2015
Chasing—and Catching—the Wild Goose, Hypothesis-Free Post-Hoc Stratification Studies as a New Paradigm for Drug Development.
Lindpaintner K.
Circulation: Cardiovascular Genetics
April 2015
